Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8628
Reference
MSAN(2026)05
Name
Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Department
Keywords
NHS
Scotland
Health Boards
Pharmaceutical Services
Supplies
Drug Shortages
Description
Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches are out of stock until late-February 2026. Oxybutynin 5mg and 10mg modified-release tablets remain available and can support increased demand. Oxybutynin 2.5mg/5ml and 5mg/5ml oral solutions sugar free remain available and can support increased demand. Oxybutynin 2.5mg and 5mg tablets remain available but cannot support increased demand. Alternative anticholinergic/non-anticholinergic agents for urinary incontinence remain available and can support increased demand (see additional information section).
Contact Name
Contact Email
Contact Address
Created
2026-01-30 10:22:25
Click to go back to homepage